VAPOURSOFT Trademark

Trademark Overview


On Monday, December 14, 2020, a trademark application was filed for VAPOURSOFT with the United States Patent and Trademark Office. The USPTO has given the VAPOURSOFT trademark a serial number of 79302420. The federal status of this trademark filing is REGISTERED as of Tuesday, January 17, 2023. This trademark is owned by Consort Medical Limited. The VAPOURSOFT trademark is filed in the Medical Instrument Products category with the following description:

Hydrofluoroalkanes (HFA) powered and liquefied gas powered apparatus and instruments for use in or in relation to drug and pharmaceutical delivery devices, namely, hydrofluoroalkanes (HFA) powered drug delivery systems in the nature of infusion and injection devices for administering drugs; hydrofluoralkanes (HFA) powered medical syringes, medical fluid auto-injectors for administering pharmaceuticals and drugs and apparatus and devices for the inhalation or injection of pharmaceuticals and drugs, namely, injection needles, medical fluid auto-injectors and syringes; hydrofluoralkanes (HFA) powered catheters, transfusion sets and injection syringes for administering drugs and pharmaceuticals, and also incorporating audio, visual and/or tactile patient feedback mechanisms relating to drug and pharmaceutical delivery dosage, measuring and monitoring information; hydrofluoralkanes (HFA) powered medical syringes, medical fluid auto-injectors, drug delivery systems comprised of implantable d...
vapoursoft

General Information


Serial Number79302420
Word MarkVAPOURSOFT
Filing DateMonday, December 14, 2020
Status700 - REGISTERED
Status DateTuesday, January 17, 2023
Registration Number6951809
Registration DateTuesday, January 17, 2023
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 1, 2022

Trademark Statements


Goods and ServicesHydrofluoroalkanes (HFA) powered and liquefied gas powered apparatus and instruments for use in or in relation to drug and pharmaceutical delivery devices, namely, hydrofluoroalkanes (HFA) powered drug delivery systems in the nature of infusion and injection devices for administering drugs; hydrofluoralkanes (HFA) powered medical syringes, medical fluid auto-injectors for administering pharmaceuticals and drugs and apparatus and devices for the inhalation or injection of pharmaceuticals and drugs, namely, injection needles, medical fluid auto-injectors and syringes; hydrofluoralkanes (HFA) powered catheters, transfusion sets and injection syringes for administering drugs and pharmaceuticals, and also incorporating audio, visual and/or tactile patient feedback mechanisms relating to drug and pharmaceutical delivery dosage, measuring and monitoring information; hydrofluoralkanes (HFA) powered medical syringes, medical fluid auto-injectors, drug delivery systems comprised of implantable drug delivery ports incorporating audio, visual and/or tactile patient feedback mechanisms to convey dosage, measuring, and monitoring data for the purpose of facilitating and monitoring drug and pharmaceutical delivery and administration; medical syringes; medical syringe stoppers; hydrofluoroolefin (HFO) powered medical fluid auto-injectors and medical fluid injectors; hydrofluoroolefin (HFO) powered apparatus and devices for administering pharmaceuticals and drugs, namely, medical apparatus in the nature of infusion and injection devices for administering drugs, medical tubing for administering drugs, and hypodermic needles; hydrofluoroolefin (HFO) powered drug delivery apparatus, namely, drug delivery systems comprised of drug delivery catheters and electromagnetic drug delivery apparatus for medical use; medical fluid auto-injectors; medical fluid injectors; disposable syringes and medical fluid injectors; hypodermic syringes; apparatus and devices for administering pharmaceuticals and drugs, namely, medical apparatus in the nature of infusion and injection devices for administering drugs, medical tubing for administering drugs, and hypodermic needles; sterile medical syringes and medical fluid auto-injectors for the administration of pharmaceuticals and drugs; cartridges sold empty and specially adapted for medical syringes; nozzles sold empty and specially adapted for medical syringes; drug delivery apparatus, namely, drug delivery systems comprised of drug delivery catheters and electromagnetic drug delivery apparatus for medical use; oral and nasal medication dispensers, namely, aerosol dispensers for medical use; aerosol dispensers for medical purposes; structural replacement parts and fittings for all the aforesaid goods

Classification Information


International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status Code6 - Active
Class Status DateTuesday, January 19, 2021
Primary Code010
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameConsort Medical Limited
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressGB

Party NameConsort Medical Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressGB

Party NameConsort Medical Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressGB

Trademark Events


Event DateEvent Description
Thursday, January 14, 2021SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Tuesday, January 19, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, January 23, 2021APPLICATION FILING RECEIPT MAILED
Monday, June 7, 2021ASSIGNED TO EXAMINER
Friday, June 11, 2021NON-FINAL ACTION WRITTEN
Saturday, June 12, 2021NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Monday, June 21, 2021REFUSAL PROCESSED BY MPU
Monday, June 21, 2021NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sunday, July 18, 2021REFUSAL PROCESSED BY IB
Wednesday, November 3, 2021CORRECTION TRANSACTION RECEIVED FROM IB
Thursday, December 16, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, December 16, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, December 17, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, January 12, 2022CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED
Tuesday, February 8, 2022ATTORNEY REVIEW COMPLETED
Tuesday, February 8, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, February 8, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, March 9, 2022NON-FINAL ACTION WRITTEN
Wednesday, March 9, 2022NON-FINAL ACTION E-MAILED
Wednesday, March 9, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sunday, April 10, 2022REFUSAL PROCESSED BY IB
Wednesday, September 7, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, September 7, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, September 8, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, September 23, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 12, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, October 12, 2022NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, October 12, 2022NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Monday, October 31, 2022NOTIFICATION PROCESSED BY IB
Tuesday, November 1, 2022PUBLISHED FOR OPPOSITION
Tuesday, November 1, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 22, 2022NEW REPRESENTATIVE AT IB RECEIVED
Tuesday, January 17, 2023REGISTERED-PRINCIPAL REGISTER
Tuesday, January 17, 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED
Monday, April 17, 2023FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Wednesday, April 26, 2023FINAL DISPOSITION PROCESSED
Wednesday, April 26, 2023FINAL DISPOSITION NOTICE SENT TO IB
Tuesday, May 16, 2023FINAL DECISION TRANSACTION PROCESSED BY IB
Thursday, February 29, 2024INTERNATIONAL REGISTRATION RENEWED
Thursday, December 11, 2025NEW REPRESENTATIVE AT IB RECEIVED